Maze Therapeutics (MAZE) Current Leases (2024 - 2026)

Maze Therapeutics has reported Current Leases for 3 years, with the latest figure at $4.8 million in Q1 2026.

• Quarterly Current Leases rose 3.51% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (up 3.51% YoY) and the FY2025 annual result came in at $4.8 million, up 3.52% from the prior year.
• Current Leases improved to $4.8 million in Q1 2026 per MAZE's latest filing, from $4.8 million in the prior quarter.
• Over five years, Current Leases peaked at $4.8 million in Q1 2026 and troughed at $4.6 million in Q4 2024.
• A 3-year average of $4.7 million and a median of $4.7 million in 2025 frame the typical range for Current Leases.
• The sharpest annual moves came in 2025 and 2026: Current Leases increased 3.52% in 2025, then climbed 3.51% in 2026.
• Over 3 years, Current Leases stood at $4.6 million in 2024, then grew by 3.52% to $4.8 million in 2025, then rose by 0.9% to $4.8 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $4.8 million, $4.8 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.